{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:44:20Z","timestamp":1788090260495,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glanzmann Thrombasthenia (GT) is a congenital platelet disorder characterized by a life-long bleeding tendency, historically considered protective against thrombosis. This report describes a rare case of pulmonary embolism (PE) in a patient with GT, challenging this assumption and highlighting a critical management paradox. A 55-year-old woman with GT underwent elective cervical discectomy. Her perioperative hemostatic regimen included a single prophylactic dose of recombinant Factor VIIa (90\u00a0\u00b5g\/kg), platelet transfusions (preoperative and daily for 3 days), and tranexamic acid. Two months postoperatively, she presented with hemoptysis. CT pulmonary angiography confirmed bilateral segmental and subsegmental PE with pulmonary infarctions. Anticoagulation with apixaban was initiated, leading to symptom resolution and thrombus regression. Therapy was discontinued after four months following a spontaneous hemarthrosis, which was managed successfully. Provoked PE can occur in GT patients following major surgery and hemostatic support. Apixaban was effective for short-term treatment, but the subsequent bleeding complication highlights the narrow therapeutic window and the need to limit anticoagulation duration in this population.<\/jats:p>","DOI":"10.1007\/s00277-026-06732-8","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:04:38Z","timestamp":1769497478000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pulmonary thromboembolism in Glanzmann Thrombasthenia: a case report and systematic literature review"],"prefix":"10.1007","volume":"105","author":[{"given":"Tayebe","family":"Mohammad Alizade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reihaneh","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Kazemizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6700-3570","authenticated-orcid":false,"given":"Niloofar","family":"Khoshnam Rad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,27]]},"reference":[{"key":"6732_CR1","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/JBM.S271744","volume":"12","author":"N Mathews","year":"2021","unstructured":"Mathews N, Rivard G-E, Bonnefoy A (2021) Glanzmann thrombasthenia: perspectives from clinical practice on accurate diagnosis and optimal treatment strategies. J Blood Med 12:449\u2013463","journal-title":"J Blood Med"},{"issue":"5","key":"6732_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.blre.2017.03.005","volume":"31","author":"AT Nurden","year":"2017","unstructured":"Nurden AT (2017) Should studies on Glanzmann thrombasthenia not be telling us more about cardiovascular disease and other major illnesses? Blood Rev 31(5):287\u2013299","journal-title":"Blood Rev"},{"issue":"4","key":"6732_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100183","volume":"7","author":"L Sattler","year":"2023","unstructured":"Sattler L, Wimmer J, Herb A, Gerout A-C, Feugeas O, Desprez D (2023) Apixaban for treatment of venous thromboembolism in an obese patient with Glanzmann thrombasthenia. Res Pract Thromb Haemost 7(4):100183","journal-title":"Res Pract Thromb Haemost"},{"key":"6732_CR4","doi-asserted-by":"crossref","unstructured":"Schutgens REG, Urbanus RT (2021) Glanzmann thrombasthenia complicated by frequent myeloproliferative neoplasm-related thromboembolism: thrombosis occurring regardless of \u03b1IIb\u03b2III integrin deficiency. Clin Case Rep 9(9):e04757","DOI":"10.1002\/ccr3.4757"},{"issue":"6","key":"6732_CR5","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/j.1365-2516.2007.01555.x","volume":"13","author":"R PHILLIPS","year":"2007","unstructured":"PHILLIPS R, RICHARDS M (2007) Venous thrombosis in Glanzmann\u2019s thrombasthenia. Haemophilia 13(6):758\u2013759","journal-title":"Haemophilia"},{"issue":"4","key":"6732_CR6","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.thromres.2010.10.012","volume":"127","author":"MA Refaai","year":"2011","unstructured":"Refaai MA, Phipps RP, Spinelli SL, Blumberg N (2011) Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes. Thromb Res 127(4):287\u2013291","journal-title":"Thromb Res"},{"issue":"05","key":"6732_CR7","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1160\/TH03-10-0638","volume":"91","author":"G Gerotziafas","year":"2004","unstructured":"Gerotziafas G, Chakroun T, Depasse F, Arzoglou P, Samama M, Elalamy I (2004) The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 91(05):977\u2013985","journal-title":"Thromb Haemost"},{"issue":"S1","key":"6732_CR8","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1111\/jth.12915","volume":"13","author":"BS Coller","year":"2015","unstructured":"Coller BS (2015) \u03b1IIb\u03b23: structure and function. J Thromb Haemost 13(S1):S17\u201325","journal-title":"J Thromb Haemost"},{"issue":"8","key":"6732_CR9","first-page":"1038","volume":"100","author":"M-C Poon","year":"2015","unstructured":"Poon M-C, d\u2019Oiron R, Zotz RB, Bindlslev N, Di Minno MND, Di Minno G (2015) The international prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention. Haematologica 100(8):1038\u201344","journal-title":"Haematologica"},{"issue":"6","key":"6732_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/j.1538-7836.2004.00759.x","volume":"2","author":"T Abshire","year":"2004","unstructured":"Abshire T, Kenet G (2004) Recombinant factor viia: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2(6):899\u2013909","journal-title":"J Thromb Haemost"},{"issue":"1","key":"6732_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.amjmed.2004.01.018","volume":"117","author":"M Cushman","year":"2004","unstructured":"Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P et al (2004) Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 117(1):19\u201325","journal-title":"Am J Med"},{"issue":"3","key":"6732_CR12","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.jvs.2012.07.020","volume":"56","author":"HT Sorensen","year":"2012","unstructured":"Sorensen HT, Svoerke C, Farkas DK (2012) Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer. J Vasc Surg 56(3):876\u2013877","journal-title":"J Vasc Surg"},{"issue":"10","key":"6732_CR13","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s40262-019-00775-z","volume":"58","author":"W Byon","year":"2019","unstructured":"Byon W, Garonzik S, Boyd RA, Frost CE (2019) Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 58(10):1265\u20131279","journal-title":"Clin Pharmacokinet"},{"issue":"15","key":"6732_CR14","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s40265-016-0644-6","volume":"76","author":"SL Greig","year":"2016","unstructured":"Greig SL, Garnock-Jones KP (2016) Apixaban: a review in venous thromboembolism. Drugs 76(15):1493\u2013504","journal-title":"Drugs"},{"issue":"4","key":"6732_CR15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.hrthm.2024.08.033","volume":"22","author":"M Shurrab","year":"2025","unstructured":"Shurrab M, Austin PC, Jackevicius CA, Tu K, Qiu F, Haldenby O et al (2025) Apixaban vs rivaroxaban in patients with atrial fibrillation at high or low bleeding risk: a population-based cohort study. Heart Rhythm 22(4):961\u201370","journal-title":"Heart Rhythm"},{"key":"6732_CR16","doi-asserted-by":"crossref","unstructured":"Chen A, Stecker E, Warden AB (2020) Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc 9(13):e017559","DOI":"10.1161\/JAHA.120.017559"},{"issue":"6","key":"6732_CR17","doi-asserted-by":"publisher","first-page":"e900","DOI":"10.1097\/HS9.0000000000000900","volume":"7","author":"REG Schutgens","year":"2023","unstructured":"Schutgens REG, Jimenez-Yuste V, Escobar M, Falanga A, Gigante B, Klamroth R et al (2023) Antithrombotic treatment in patients with hemophilia: an EHA-ISTH-EAHAD-ESO clinical practice guidance. HemaSphere 7(6):e900","journal-title":"HemaSphere"},{"issue":"2","key":"6732_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jtha.2024.10.033","volume":"23","author":"M Escobar","year":"2025","unstructured":"Escobar M, Lassila R, Bekdache C, Owaidah T, Sholzberg M (2025) Use of antithrombotic therapy in patients with hemophilia: a selected synopsis of the European hematology association - International society on thrombosis and haemostasis - European association for hemophilia and allied disorders - European stroke organi. J Thromb Haemost 23(2):745\u2013749","journal-title":"J Thromb Haemost"},{"issue":"6","key":"6732_CR19","doi-asserted-by":"publisher","first-page":"e531","DOI":"10.1111\/hae.13350","volume":"23","author":"A Ferretti","year":"2017","unstructured":"Ferretti A, Santoro C, Ferrara G, Baldacci E, Barone F, Mazzucconi MG (2017) Anticoagulant therapy in patients with glanzmann\u2019s thrombasthenia: is it possible? Haemophilia 23(6):e531\u2013e533","journal-title":"Haemophilia"},{"issue":"1","key":"6732_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/j.1365-2141.2011.08821.x","volume":"156","author":"SM Rezende","year":"2012","unstructured":"Rezende SM (2012) Secondary prophylaxis with warfarin for recurrent thrombosis in a patient with Glanzmann thrombasthenia and F5 G1691A. Br J Haematol 156(1):144\u2013144","journal-title":"Br J Haematol"},{"issue":"2","key":"6732_CR21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1046\/j.1538-7836.2003.00041.x","volume":"1","author":"H Ten Cate","year":"2003","unstructured":"Ten Cate H, Brandjes DPM, Smits PHM, Van Mourik JA (2003) The role of platelets in venous thrombosis: a patient with Glanzmann\u2019s thrombasthenia and a factor V Leiden mutation suffering from deep venous thrombosis. J Thromb Haemost 1(2):394\u20135","journal-title":"J Thromb Haemost"},{"issue":"2","key":"6732_CR22","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood.V90.2.888","volume":"90","author":"Y Gruel","year":"1997","unstructured":"Gruel Y, Pacouret G, Bellucci S, Caen J (1997) Severe proximal deep vein thrombosis in a Glanzmann thrombasthenia variant successfully treated with a low molecular weight heparin. Blood 90(2):888\u2013889","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06732-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06732-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06732-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T07:03:35Z","timestamp":1771398215000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06732-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,27]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["6732"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06732-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,27]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for participation in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During the preparation of this work, the authors used DeepSeek AI solely for the purpose of improving language, readability, and grammar. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the final version of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Artificial intelligence assistance"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}